0001192482-18-000329.txt : 20180702 0001192482-18-000329.hdr.sgml : 20180702 20180702174447 ACCESSION NUMBER: 0001192482-18-000329 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20180701 FILED AS OF DATE: 20180702 DATE AS OF CHANGE: 20180702 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Ciaffoni Joseph CENTRAL INDEX KEY: 0001443841 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-37372 FILM NUMBER: 18934138 MAIL ADDRESS: STREET 1: C/O ENDO HEALTH SOLUTIONS INC. STREET 2: 1400 ATWATER DRIVE CITY: MALVERN STATE: PA ZIP: 19355 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: COLLEGIUM PHARMACEUTICAL, INC CENTRAL INDEX KEY: 0001267565 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 STATE OF INCORPORATION: VA FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 780 DEDHAM STREET, SUITE 800 CITY: CANTON STATE: MA ZIP: 02021 BUSINESS PHONE: 781-713-3699 MAIL ADDRESS: STREET 1: 780 DEDHAM STREET, SUITE 800 CITY: CANTON STATE: MA ZIP: 02021 FORMER COMPANY: FORMER CONFORMED NAME: COLLEGIUM PHARMACEUTICAL INC DATE OF NAME CHANGE: 20031020 4 1 edgar.xml PRIMARY DOCUMENT X0306 4 2018-07-01 0001267565 COLLEGIUM PHARMACEUTICAL, INC COLL 0001443841 Ciaffoni Joseph C/O COLLEGIUM PHARMACEUTICAL, INC. 780 DEDHAM STREET, SUITE 800 CANTON MA 02021 1 1 0 0 President and CEO Common Stock 2018-07-01 4 A 0 25140 0 A 113341 D Stock Option (Right to Purchase) 23.85 2018-07-01 4 A 0 41418 0 A 2028-07-01 Common Stock 41418 41418 D Reflects the grant of restricted stock units in connection with the reporting person's promotion to Chief Executive Officer of the issuer. Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock. Twenty-five percent (25%) of the restricted stock units vest on July 1, 2019, and the balance of the restricted stock units vest in equal installments every six months (in each case, rounded up to the nearest whole share of common stock) over the following three-year period, subject to the reporting person's continued service with the issuer. The restricted stock units will be settled on each applicable vesting date in shares of the issuer's common stock. Twenty-five percent (25%) of the option vests and becomes exercisable on July 1, 2019, and the balance vests in equal quarterly installments (rounded up to the nearest whole share of common stock) over the following three-year period, subject to the reporting person's continued service with the issuer. /s/ Paul Brannelly as Attorney-In-Fact For Joseph Ciaffoni 2018-07-02